AbbVie maintains growth as life beyond Humira edges closer

2 February 2022
abbvie_headquarters_large

US drugmaker AbbVie (NYSE: ABBV) has presented its fourth-quarter and full-year 2021 financial results.

The company’s net revenues for the quarter were $14.89 billion, an increase of 7.4% on a reported basis but slightly below analysts’ estimates of $14.97 billion. Excluding items, AbbVie earned $3.31 per share, beating Wall Street predictions of $3.29 per share.

For 2021 as a whole, net revenues were $56.2 billion, an increase of 22.7%, while adjusted earnings were $12.70, up 20%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical